Switch theme
Sign up to access all valuation multiples
PharmaSGP Holding SE is a pharmaceutical company. The company develops chemical-free, over-the-counter (OTC) drugs and healthcare products. The product portfolio includes RUBAXX for rheumatic pain Restaxil for nerve pain, and Deseo for sexual dysfunction. It has established various consumer brands in important indication areas, such as rheumatic and neuralgic pain or sexual weakness Also, the company offers products for skin aging and vertigo.
96
Last FY Revenue $133M
Last FY EBITDA $44.5M
$320M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, PharmaSGP achieved revenue of $133M and an EBITDA of $44.5M.
PharmaSGP expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PharmaSGP valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $133M | XXX | XXX | XXX |
| Gross Profit | XXX | $121M | XXX | XXX | XXX |
| Gross Margin | XXX | 91% | XXX | XXX | XXX |
| EBITDA | XXX | $44.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 33% | XXX | XXX | XXX |
| EBIT | XXX | $31.0M | XXX | XXX | XXX |
| EBIT Margin | XXX | 23% | XXX | XXX | XXX |
| Net Profit | XXX | $21.9M | XXX | XXX | XXX |
| Net Margin | XXX | 16% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, PharmaSGP's stock price is EUR 27 (or $30).
PharmaSGP has current market cap of EUR 311M (or $349M), and EV of EUR 285M (or $320M).
See PharmaSGP trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $320M | $349M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, PharmaSGP has market cap of $349M and EV of $320M.
PharmaSGP's trades at 2.4x EV/Revenue multiple, and 7.2x EV/EBITDA.
Equity research analysts estimate PharmaSGP's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PharmaSGP's P/E ratio is not available.
See valuation multiples for PharmaSGP and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $349M | XXX | $349M | XXX | XXX | XXX |
| EV (current) | $320M | XXX | $320M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 7.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 10.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 15.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 12.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPharmaSGP's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $0.9M for the same period.
PharmaSGP's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PharmaSGP's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for PharmaSGP and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 33% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | 5% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 68% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PharmaSGP acquired XXX companies to date.
Last acquisition by PharmaSGP was XXXXXXXX, XXXXX XXXXX XXXXXX . PharmaSGP acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is PharmaSGP headquartered? | PharmaSGP is headquartered in Germany. |
| How many employees does PharmaSGP have? | As of today, PharmaSGP has 96 employees. |
| Who is the CEO of PharmaSGP? | PharmaSGP's CEO is Ms. Natalie Weigand. |
| Is PharmaSGP publicy listed? | Yes, PharmaSGP is a public company listed on BER. |
| What is the stock symbol of PharmaSGP? | PharmaSGP trades under PSG ticker. |
| When did PharmaSGP go public? | PharmaSGP went public in 2020. |
| Who are competitors of PharmaSGP? | Similar companies to PharmaSGP include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of PharmaSGP? | PharmaSGP's current market cap is $349M |
| Is PharmaSGP profitable? | Yes, PharmaSGP is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
